Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a
dismal prognosis, with only modest advances in therapeutic strategies over the past several …

Small cell lung cancer (SCLC) is a rapidly growing, highly metastatic, and relatively immune-
cold lung cancer subtype. Historically viewed in the laboratory and clinic as a single …

Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …

Cancer heterogeneity impacts therapeutic response, driving efforts to discover over-arching
rules that supersede variability. Here, we define pan-cancer binary classes based on distinct …

Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse
primary sites that lack effective treatments. Using chemical genetic screens, we identified …

Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct
transcriptional subtypes, but implementing subtyping in the clinic has remained challenging …

Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key
transcription regulators have recently been proposed in cell lines and limited number of …

Introduction A new molecular subtype classification was recently proposed for SCLC. It is
necessary to validate it in primary SCLC tumors by immunohistochemical (IHC) staining and …

We performed comprehensive proteogenomic characterization of small cell lung cancer
(SCLC) using paired tumors and adjacent lung tissues from 112 treatment-naive patients …

Although several ATR inhibitors are in development, there are unresolved questions
regarding their differential potency, molecular signatures of patients with cancer for …